GlassScriptPhysician profile
Ryan C Tulowitzki
NPI 1134488521
$2,397.13
in general payments reported to CMS, 2019-2025
23 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $398 · 2021: $328 · 2022: $434 · 2023: $372 · 2024: $234 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $652.85 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $258.14 | 2019-2023 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $223.57 | 2019-2023 | Farxiga |
| Daiichi Sankyo INC. | $180.89 | 2019-2025 | Injectafer |
| Amgen INC. | $178.59 | 2024-2025 | Krystexxa, Tavneos |
| Bard Peripheral Vascular, INC. | $137.41 | 2020 | |
| Akebia Therapeutics INC | $122.83 | 2020-2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $88.89 | 2019-2022 | |
| Nxstage Medical, INC. | $85.48 | 2023 | Liberty Select Cycler, Nxstage System One |
| Bayer Healthcare Pharmaceuticals INC. | $71.66 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $71.23 | 2023-2025 | |
| Vifor Pharma, INC. | $56.07 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $52.61 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $39.68 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.96 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Calliditas Therapeutics US INC. | $22.13 | 2024 | |
| Genzyme Corporation | $20.27 | 2019 | |
| Ardelyx, INC. | $18.61 | 2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $18.08 | 2019 | |
| Lilly USA, LLC | $16.56 | 2024 | Jardiance |
| Travere Therapeutics, INC. | $14.61 | 2023 | |
| Aurinia Pharma U.S., INC. | $13.75 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Tulowitzki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.